Daclatasvir Dihydrochloride
| Product Name | Daclatasvir Dihydrochloride |
|---|---|
| Alternate Names | Daclatasvir Impurities, Impurities of Daclatasvir |
| CAT No. | CS-O-13072 |
| CAS No. | 1009119-65-6 |
| Category | Impurities |
| Stock | IN-Stock |
| Mol. Wt. | 811.80 g/mol |
| Mol. For. | C₄₀H₅₂Cl₂N₈O₆ |
| Hazardous | This is a Hazardous Compound |
| COA | View Sample COA |
| MSDS | View Sample MSDS |
| Parent API | Daclatasvir |
| Therapeutic | Antiretroviral / Anti-HIV |
| Smileys | O=C(N1[C@H](C2=NC=C(C3=CC=C(C4=CC=C(C5=CN=C([C@H](CCC6)N6C([C@H](C(C)C)NC(OC)=O)=O)N5)C=C4)C=C3)N2)CCC1)[C@H](C(C)C)NC(OC)=O.Cl.Cl |
| Canonical Smiles | CC(C)C(C(=O)N1CCCC1C2=NC=C(N2)C3=CC=C(C=C3)C4=CC=C(C=C4)C5=CN=C(N5)C6CCCN6C(=O)C(C(C)C)NC(=O)OC)NC(=O)OC.Cl.Cl |
| InchIKey | BVZLLUDATICXCI-JMSCDMLISA-N |
| Inchl | InChI=1S/C40H50N8O6.2ClH/c1-23(2)33(45-39(51)53-5)37(49)47-19-7-9-31(47)35-41-21-29(43-35)27-15-11-25(12-16-27)26-13-17-28(18-14-26)30-22-42-36(44-30)32-10-8-20-48(32)38(50)34(24(3)4)46-40(52)54-6;;/h11-18,21-24,31-34H,7-10,19-20H2,1-6H3,(H,41,43)(H,42,44)(H,45,51)(H,46,52);2*1H/t31-,32-,33-,34-;;/m0../s1 |
| IUPAC | methyl N-[(2S)-1-[(2S)-2-[5-[4-[4-[2-[(2S)-1-[(2S)-2-(methoxycarbonylamino)-3-methylbutanoyl]pyrrolidin-2-yl]-1H-imidazol-5-yl]phenyl]phenyl]-1H-imidazol-2-yl]pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]carbamate;dihydrochloride |
| Controlled | No |
| Shipping | Free for purchase above 1000$ |
| Delivery | In-Stock, products will be dispatched within 24 hours via FedEx for USA, Europe, and other countries. |
| Return | Returns/replacement accepted if you are not satisfied with the quality of the product, (please send us an email with the reason/issues which are facing, within 15 days, after receipt of the product). |
| Ordering | Place your order online or by email sales@clearsynth.com |
Daclatasvir Dihydrochloride is a medication that is used in combination with other antiviral agents to treat chronic hepatitis C infections. It is an antiviral drug that belongs to a class of medications known as NS5A inhibitors. Daclatasvir Dihydrochloride works by blocking the replication of the hepatitis C virus, thereby preventing the virus from spreading and causing further damage to the liver.
The chemical formula for Daclatasvir Dihydrochloride is C40H50N8O6S2. It is a white to off-white powder that is soluble in water and methanol. The molecular weight of Daclatasvir Dihydrochloride is 738.95 g/mol.
Daclatasvir Dihydrochloride is administered orally in the form of a tablet. The recommended dose is 60 mg once daily. It can be taken with or without food. The duration of treatment varies depending on the severity of the infection and the response to treatment. Typically, treatment lasts for 12-24 weeks.
Daclatasvir Dihydrochloride is generally well-tolerated. However, it may cause some side effects, such as headache, fatigue, nausea, and diarrhea. Serious side effects are rare but may include allergic reactions, liver problems, and a decrease in red blood cell count.
In conclusion, Daclatasvir Dihydrochloride is an effective medication for the treatment of chronic hepatitis C infections. It works by blocking the replication of the virus and preventing further damage to the liver. It is generally well-tolerated but may cause some side effects. It should only be used under the guidance of a healthcare provider.
Get an Instant Quote
Related Compounds
Daclatasvir Impurity-X | Monodes(N-carboxymethyl)valine Daclatasvir | Daclatasvir Impurity-P | Daclatasvir Impurity 5 (SRSS-Isomer) | Daclatasvir SRSR Isomer | Daclatasvir Impurity-E | Daclatasvir Tert butyl ester | Daclatasvir Impurity-T | Daclatasvir Impurity 4 | Daclatasvir Impurity-R | Daclatasvir dihydrochloride nitrosamine impurity | Daclatasvir Impurity-Z | N-Acetyl Daclatasvir | Daclatasvir Impurity-H | Daclatasvir Impurity-D | Daclatasvir Enantiomer 2HCl | Daclatasvir Impurity-B | Daclatasvir Impurity-C | Daclatasvir Impurity-G | Daclatasvir Impurity-A | Daclatasvir Impurity-Q | Daclatasvir RRRR Isomer Enantiomer (2HCl) | Daclatasvir RRSS Isomer | Daclatasvir Impurity-Y |